Abltide
The Abltide peptide sequence (EAIYAAPFAKKK) is based on the C-terminus of Abl.
Catalog No. A02-58
| Catalog No. | Pack Size | Price (USD) | |
|---|---|---|---|
| A02-58-1000 | 1 mg | $83 | |
| A02-58-BULK | BULK | Contact Us |
The Abltide peptide sequence (EAIYAAPFAKKK) is based on the C-terminus of Abl.
Catalog No. A02-58
| Catalog No. | Pack Size | Price (USD) | |
|---|---|---|---|
| A02-58-1000 | 1 mg | $83 | |
| A02-58-BULK | BULK | Contact Us |
No overview information available.
Purity:
Determined to be 97.7% by HPLC analysis.
Storage, Stability and Shipping:
Store product at –20oC. For optimal storage, aliquot diluted product into smaller quantities and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Molecular Weight:
1336.6
Freidman R et al., The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia. Biochimica et Biophysica Acta April 2019 10.1016/j.bbagen.2019.01.011
Buffa Pietro et al., BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein FASEB Journal December 2013 10.1096/fj.13-236992
Massimino Michele et al., IRF5 IS A TARGET OF BCR-ABL KINASE ACTIVITY AND REDUCES CML CELL PROLIFERATION Carcinogenesis January 2014 10.1093/carcin/bgu013
Ghadiali JE et al., Protein Kinase-Actuated Resonance Energy Transfer in Quantum Dot-Peptide Conjugates ACS Nano July 2010 10.1021/nn101293s
et al., Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts Frontiers in Pharmacology June 2021
Cancer, Cell Cycle, Cytoplasmic Tyrosine Kinases, Inflammation, Invasion/Metastasis, Neurobiology
ABL1, Active, A03-18H
RET (Y791F), Active, R02-12CG
ABL1 (Q252H), Active, A03-12FG
ABL1 (F317I), Active, A03-12JG
STAY CONNECTED
Fax: 1-604-232-4601
Toll Free: 1-866-954-6273
info@signalchem.com